Mucin-1

"Mucin-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.

Descriptor ID	D018396
MeSH Number(s)	D12.776.395.550.560 D12.776.395.560.631.115 D12.776.543.550.530 D23.050.285.050.300 D23.050.550.325.300 D23.101.140.075.300
Concept/Terms	Mucin-1 Mucin-1 Mucin 1 CA 15.3 Antigen Antigen, CA 15.3 Antigen CA-15-3 Antigen CA 15 3 CA-15-3, Antigen CA-15-3 Antigen Antigen, CA-15-3 Episialin CD227 Antigen Antigen, CD227 Polymorphic Epithelial Mucin Epithelial Membrane Antigen Antigen, Epithelial Membrane Membrane Antigen, Epithelial Muc1 Mucin Mucin, Muc1 Antigens, CD227 CD227 Antigens CA 15-3 Antigen Antigen, CA 15-3 CA 15 3 Antigen Epithelial Mucin, Polymorphic Mucin, Polymorphic Epithelial

Below are MeSH descriptors whose meaning is more general than "Mucin-1".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Glycoproteins [D12.776.395]
Membrane Glycoproteins [D12.776.395.550]
Mucin-1 [D12.776.395.550.560]
Mucoproteins [D12.776.395.560]
Mucins [D12.776.395.560.631]
Mucin-1 [D12.776.395.560.631.115]
Membrane Proteins [D12.776.543]
Membrane Glycoproteins [D12.776.543.550]
Mucin-1 [D12.776.543.550.530]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Neoplasm [D23.050.285]
Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]
Mucin-1 [D23.050.285.050.300]
Epitopes [D23.050.550]
Antigens, Tumor-Associated, Carbohydrate [D23.050.550.325]
Mucin-1 [D23.050.550.325.300]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Antigens, Tumor-Associated, Carbohydrate [D23.101.140.075]
Mucin-1 [D23.101.140.075.300]

Below are MeSH descriptors whose meaning is related to "Mucin-1".

Below are MeSH descriptors whose meaning is more specific than "Mucin-1".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Mucin-1" by people in this website by year, and whether "Mucin-1" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2004 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	2	0	2
2006	1	0	1
2007	1	0	1
2011	1	0	1
2013	0	1	1
2015	0	1	1
2017	1	1	2

Below are the most recent publications written about "Mucin-1" by people in Profiles.

Boll EJ, Ayala-Lujan J, Szabady RL, Louissaint C, Smith RZ, Krogfelt KA, Nataro JP, Ruiz-Perez F, McCormick BA. Enteroaggregative Escherichia coli Adherence Fimbriae Drive Inflammatory Cell Recruitment via Interactions with Epithelial MUC1. mBio. 2017 06 06; 8(3).

View in: PubMed
Cho WC, Wagner B, Gulosh M, Elaba Z. Syringoid Eccrine Carcinoma of the Foot: Report of a Rare Cutaneous Adnexal Neoplasm. Int J Surg Pathol. 2017 Oct; 25(7):659-664.

View in: PubMed
Schwager ZA, Mannava KA, Mannava S, Telang GH, Robinson-Bostom L, Jellinek NJ. Superficial acral fibromyxoma and other slow-growing tumors in acral areas. Cutis. 2015 Feb; 95(2):E15-9.

View in: PubMed
Davison JM, Ellis ST, Foxwell TJ, Luketich JD, Gibson MK, Kuan SF, Nason KS. MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas. Hum Pathol. 2014 Mar; 45(3):540-8.

View in: PubMed
Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Philip R, Dobrzanski MJ, Lockwood-Cooke PR, Robinson W. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother. 2012 Feb-Mar; 35(2):196-204.

View in: PubMed
Dobrzanski MJ, Rewers-Felkins KA, Samad KA, Quinlin IS, Phillips CA, Robinson W, Dobrzanski DJ, Wright SE. Immunotherapy with IL-10- and IFN-?-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother. 2012 Jun; 61(6):839-54.

View in: PubMed
Kuperman M, Florence RR, Pantanowitz L, Visintainer PF, Cibas ES, Otis CN. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach. Diagn Cytopathol. 2013 Feb; 41(2):131-40.

View in: PubMed
Wright SE, Quinlin IS, Rewers-Felkins KA, Dombrowski KE, Phillips CA. Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions. Immunopharmacol Immunotoxicol. 2010 Dec; 32(4):647-55.

View in: PubMed
Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Philip R, Zorsky P, Klug P, Dai L, Hussain M, Thomas AA, Sundaramurthy C. Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study. Immunol Invest. 2010; 39(6):570-86.

View in: PubMed
Dobrzanski MJ, Rewers-Felkins KA, Quinlin IS, Samad KA, Phillips CA, Robinson W, Dobrzanski DJ, Wright SE. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol. 2009 Dec; 133(3):333-52.

View in: PubMed

People

Explore

Similar Concepts

Top Journals